BioAlliance Pharma Presents Additional US Pivotal Phase III Results on Loramyc[TM] (Miconazole Lauriad[R]) at the 47Th Annual Meeting of the IDSA.

PARIS -- Regulatory News:

BioAlliance Pharma SA (Paris:BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented results on miconazole Lauriad([R]) at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia (October 29 - November 1st).

The additional results from BioAlliance Pharma's pivotal Phase III study with miconazole Lauriad([R]) mucoadhesive buccal tablets (MBT) demonstrated comparable efficacy and safety profile to that of clotrimazole troches (administered five times per day) for oropharyngeal candidiasis (OPC), in HIV-positive patients in 40 sites in the United States, Canada and South Africa. The data also demonstrated a good patient compliance as a result of the added convenience of a once-a-day dosing.

This presentation was given by Dr Rajesh V. Lalla, oral medicine specialist, from the University of Connecticut Health Center.

OPC, also known as thrush, is an oral fungal infection most common in individuals with weakened immune systems - particularly those with HIV/AIDS and those undergoing cancer treatments. OPC is a disruptive condition that results in lesions and inflammation in the mouth, and includes symptoms such as soreness, burning and/or altered taste.

About IDSA

The Infectious Diseases Society of America (IDSA) represents physicians, scientists and other health care professionals who specialize in infectious diseases. IDSA's purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases.

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops and markets innovative products in France, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at http://www.bioalliancepharma.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma S.A.'s website (http://www.bioalliancepharma.com).